ANI Pharmaceuticals, Inc.
ANIP
$82.10
-$0.58-0.70%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 7.78% | 7.23% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 7.78% | 7.23% | |||
| Cost of Revenue | 25.16% | 2.16% | |||
| Gross Profit | -1.71% | 10.21% | |||
| SG&A Expenses | -6.52% | 7.86% | |||
| Depreciation & Amortization | -2.79% | 1.70% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 4.38% | 7.62% | |||
| Operating Income | 51.16% | 2.45% | |||
| Income Before Tax | 221.14% | -47.34% | |||
| Income Tax Expenses | 263.51% | -54.11% | |||
| Earnings from Continuing Operations | 211.35% | -45.48% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 211.35% | -45.48% | |||
| EBIT | 51.16% | 2.45% | |||
| EBITDA | 18.66% | 2.00% | |||
| EPS Basic | 220.99% | -47.20% | |||
| Normalized Basic EPS | 49.47% | 18.73% | |||
| EPS Diluted | 213.50% | -47.28% | |||
| Normalized Diluted EPS | 45.60% | 18.59% | |||
| Average Basic Shares Outstanding | 1.21% | 1.16% | |||
| Average Diluted Shares Outstanding | 3.87% | 1.31% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -0.73% | 0.84% | |||